Vanguard Group’s CoLucid Pharmaceuticals, Inc. CLCD Stock Holding History

Vanguard Group’s Portfolio CLCD Stock Details CLCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-370,051	Closed	-$13.5M	–	4092
2016 Q4	$13.5M	Buy	370,051 +111,726	+43%	+$3.95M	﹤0.01%	2604
2016 Q3	$9.86M	Buy	258,325 +182,083	+239%	+$2.69M	﹤0.01%	2692
2016 Q2	$623K	Buy	76,242 +900	+1%	+$6.04K	﹤0.01%	3743
2016 Q1	$467K	Buy	75,342 +15,997	+27%	+$99.9K	﹤0.01%	3804
2015 Q4	$496K	Buy	59,345 +17,302	+41%	+$91.1K	﹤0.01%	3837
2015 Q3	$163K	Buy	42,043 +12,729	+43%	+$94K	﹤0.01%	4050
2015 Q2	$261K	Buy	+29,314	New	+$252K	﹤0.01%	4000

Other funds holding CLCD

FPF

FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

Vanguard Group's CLCD Position: Q1 2017 in Review

Vanguard Group sold out of CoLucid Pharmaceuticals, Inc. (CLCD) in Q1 2017, closing a stake of 370,051 shares — an estimated $13.5M sold.

Vanguard Group first reported a position in CLCD in Q2 2015 and held it in 7 quarters. The position peaked at $13.5M in Q4 2016. 1 fund tracked by Wall St. Rank holds CLCD as of Q1 2017.

Vanguard Group reported no remaining CoLucid Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
Vanguard Group sold 370,051 CoLucid Pharmaceuticals, Inc. shares in Q1 2017, an estimated $13.5M.
Vanguard Group first reported a position in CoLucid Pharmaceuticals, Inc. in Q2 2015 and held it in 7 quarters.
Vanguard Group's CoLucid Pharmaceuticals, Inc. position peaked at $13.5M in Q4 2016.
1 fund tracked by Wall St. Rank held CoLucid Pharmaceuticals, Inc. as of Q1 2017.

Based on Vanguard Group's 13F filing for Q1 2017, filed 12 May 2017.